← Latest news 
Pfizer rallies after strong quarter and legal wins that could extend key drug profits beyond 2028
Business
Published on 5 May 2026
A patent extension and a court win reshape 2028+ growth
Pfizer reported higher-than-expected first-quarter sales and profit, boosting investor confidence. The company also pointed to a patent extension for its Vyndamax heart treatment and a favorable European court ruling tied to its COVID-19 vaccine. Together, the wins are expected to help secure stronger growth prospects after 2028.
- Pfizer beat expectations on first-quarter sales and profit
- Vyndamax gets a patent extension supporting future revenue
- A European court ruling improves outlook for its COVID-19 vaccine
- Company sees stronger growth potential after 2028
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times